Are GlaxoSmithKline plc, Tissue Regenix Group plc and Optibiotix Health plc must-have health stocks?

Are GlaxoSmithKline plc (LON:GSK), Tissue Regenix Group plc (LON:TRX) and Optibiotix Health plc (LON:OPTI) great picks for your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Top FTSE 100 pharmaceuticals group GlaxoSmithKline (LSE: GSK) may have endured a challenging few years, but it remains a core stock for a portfolio in my view.

Attractive buy

The company has come through a phase of expiring patents, which has temporarily reined-in revenue and profits, but ageing populations in the developed world and rising demand in emerging markets remain long-term drivers for growth. Glaxo is well positioned to benefit, with its four divisions of pharmaceuticals, consumer health products, vaccines and HIV medicines.

The company is set to put the recent lacklustre period behind it with a return to revenue growth this year. City analysts forecast an earnings rise of 15%, and this is expected to be just the start of a new growth trajectory. As such, Glaxo appears an attractive buy at a current share price of 1,436p on a price-to-earnings ratio of 16.4 and with a dividend yield of 5.6%.

Should you invest £1,000 in Abrdn right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Abrdn made the list?

See the 6 stocks

Commersialisation underway

Tissue Regenix (LSE: TRX) has a patented technology that decellurises animal and human tissue, leaving a “tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn out body parts”.

In its annual results released this morning, the company reported revenue of £0.8m in the first year of commercialisation of its flagship wound care product, and good clinical progress on orthopaedic and heart-valve products. Revenue is set to rise rapidly, with analysts having pencilled-in uplifts to over £3m, followed by over £10m.

As expected, Tissue Regenix reported a £10m pre-tax loss for the year just gone, reflecting its investment in commercial infrastructure and clinical trials. However, with year-end cash of £19.9m and rising revenues, the financial position of the company is strong.

With the shares modestly lower in early trading, Tissue Regenix is valued at £131m. However, the size of the regenerative medical devices market is huge and with the commercial potential of the company’s products starting to be realised, the business could come to be worth a multiple of its present value. As such, it could prove a good buy for investors looking for a higher risk/higher reward opportunity.

A speculative investment

Optibiotix Health (LSE: OPTI) is behind Tissue Regenix on the road to commercialisation, but like the regenerative tissue company, it has genuine and valuable intellectual property. In Optibiotix’s case, this is centred on tackling obesity, high cholesterol and diabetes with patented compounds that change the way microbes in the body work and interact.

Optibiotix may have no commercial revenues at this stage, but a number of joint development, cost-sharing and option agreements are in place, including with Slimfast and an unnamed “multinational consumer goods company”.

At a current share price of 80p, Optibiotix is valued at £62m. At this stage of its development, Optibiotix remains a speculative investment for those with a high tolerance for risk, but big business is clearly interested in the company’s technology and the potential markets are huge. These markets were further extend just last week when Optibiotix filed a new patent for microbial proteins with the potential to tackle hospital superbugs such as MRSA.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of British pound coins falling on list of share prices
Investing Articles

Why did the AstraZeneca share price just fall, and what should we do?

The AstraZeneca share price just took a hit as President Trump announced a price war against the US pharmaceutical industry.

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Here’s why some parts of the stock market rallied on Monday

The stock market saw an uneven rally on Monday as companies with exposure to China surged on news coming out…

Read more »

US Tariffs street sign
Investing Articles

£10k invested in Barclays shares on ‘Liberation Day’ low is now worth…

Harvey Jones looks at the damage done to Barclays' shares by Donald Trump's trade wars, and how the FTSE 100…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

At what point does it make sense for me to buy Aston Martin as a value stock?

Jon Smith wonders if this FTSE 250 company qualifies for inclusion as a value stock, or if current troubles make…

Read more »

piggy bank, searching with binoculars
Growth Shares

This FTSE 250 stock’s up 31% in the past month and I think it’s just the beginning

Jon Smith talks through a hot FTSE 250 stock that's charging higher based on strong momentum from its latest trading…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

2 top dividend stocks to consider for passive income in May

Our writer thinks these two shares are well worth checking out for investors targeting a growing stream of passive income…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

53% under its fair value, should investors consider buying this FTSE 100 banking gem right now?

This FTSE 100 bank looks extremely undervalued to me following a shift in its key banking strategy towards fee-based rather…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Under £25 now, Shell’s share price looks cheap to me anywhere below £66.43!

Shell’s share price has fallen a lot recently, but this may indicate a bargain to be had. I took a…

Read more »